1
3
4
News & Events
InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums
June 1, 2022
Intervenn to introduce a glycoproteomic option for liquid biopsies. Read more
Congenica wins Technology Company of the Year
May 12, 2022
Congenica awarded for its cutting-edge genomic platform, which enables the rapid analysis and interpretation of DNA sequencing data. Read more
Imago BioSciences Announces Completion of Enrollment in Phase 2
May 3, 2022
clinical study of bomedemstat for the treatment of essential thrombocythemia with 73 patients enrolled. Read more
6
7
News & Events
InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums
June 1, 2022
Intervenn to introduce a glycoproteomic option for liquid biopsies. Read more
Congenica wins Technology Company of the Year
May 12, 2022
Congenica awarded for its cutting-edge genomic platform, which enables the rapid analysis and interpretation of DNA sequencing data. Read more
Imago BioSciences Announces Completion of Enrollment in Phase 2
May 3, 2022
clinical study of bomedemstat for the treatment of essential thrombocythemia with 73 patients enrolled. Read more
14
Championing
collaborations
that improve health
and the quality of life
for everyone.

#JoinForces
#LifeSciencesInTheFuture
21
25
29
35
37
News & Events
InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums
June 1, 2022
Intervenn to introduce a glycoproteomic option for liquid biopsies. Read more
Congenica wins Technology Company of the Year
May 12, 2022
Congenica awarded for its cutting-edge genomic platform, which enables the rapid analysis and interpretation of DNA sequencing data. Read more
Imago BioSciences Announces Completion of Enrollment in Phase 2
May 3, 2022
clinical study of bomedemstat for the treatment of essential thrombocythemia with 73 patients enrolled. Read more
39
41